Concepts (158)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tremor | 14 | 2024 | 48 | 3.880 |
Why?
|
| Fragile X Mental Retardation Protein | 17 | 2018 | 71 | 3.840 |
Why?
|
| Fragile X Syndrome | 17 | 2024 | 124 | 3.830 |
Why?
|
| Ataxia | 13 | 2024 | 44 | 3.500 |
Why?
|
| Parkinson Disease | 5 | 2025 | 134 | 1.700 |
Why?
|
| Heterozygote | 9 | 2016 | 59 | 1.680 |
Why?
|
| Trinucleotide Repeat Expansion | 7 | 2016 | 26 | 1.460 |
Why?
|
| Postural Balance | 4 | 2025 | 26 | 1.040 |
Why?
|
| Humans | 32 | 2025 | 5837 | 1.010 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 17 | 0.890 |
Why?
|
| Health Status Disparities | 1 | 2025 | 17 | 0.880 |
Why?
|
| Female | 21 | 2025 | 3346 | 0.850 |
Why?
|
| Middle Aged | 18 | 2025 | 1775 | 0.850 |
Why?
|
| Male | 23 | 2025 | 3399 | 0.840 |
Why?
|
| Aged | 17 | 2025 | 1860 | 0.830 |
Why?
|
| Parkinsonian Disorders | 4 | 2016 | 43 | 0.830 |
Why?
|
| Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.620 |
Why?
|
| Nootropic Agents | 1 | 2020 | 7 | 0.620 |
Why?
|
| Movement Disorders | 2 | 2016 | 11 | 0.560 |
Why?
|
| Exercise Therapy | 1 | 2018 | 29 | 0.560 |
Why?
|
| Patient Selection | 1 | 2018 | 48 | 0.560 |
Why?
|
| Trinucleotide Repeats | 1 | 2018 | 9 | 0.540 |
Why?
|
| Memory Disorders | 2 | 2016 | 48 | 0.540 |
Why?
|
| Adult | 11 | 2025 | 1670 | 0.510 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 26 | 0.500 |
Why?
|
| Tinnitus | 2 | 2020 | 2 | 0.490 |
Why?
|
| DNA Methylation | 1 | 2016 | 72 | 0.480 |
Why?
|
| Phenotype | 4 | 2025 | 96 | 0.480 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2016 | 123 | 0.440 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 1034 | 0.360 |
Why?
|
| Deafness | 2 | 2022 | 4 | 0.340 |
Why?
|
| Executive Function | 1 | 2011 | 31 | 0.340 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 235 | 0.340 |
Why?
|
| Cohort Studies | 4 | 2016 | 406 | 0.330 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 409 | 0.320 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 187 | 0.300 |
Why?
|
| Prospective Studies | 3 | 2025 | 411 | 0.270 |
Why?
|
| Genetic Testing | 4 | 2014 | 18 | 0.260 |
Why?
|
| Observational Studies as Topic | 2 | 2025 | 10 | 0.260 |
Why?
|
| Treatment Outcome | 4 | 2022 | 601 | 0.260 |
Why?
|
| Cerebellar Ataxia | 1 | 2006 | 3 | 0.250 |
Why?
|
| Central Nervous System Agents | 1 | 2006 | 4 | 0.250 |
Why?
|
| Quality of Life | 2 | 2025 | 108 | 0.250 |
Why?
|
| Parietal Lobe | 1 | 2025 | 8 | 0.230 |
Why?
|
| Huntington Disease | 1 | 2025 | 19 | 0.230 |
Why?
|
| Cerebral Cortex | 1 | 2025 | 36 | 0.230 |
Why?
|
| Psychomotor Performance | 1 | 2025 | 48 | 0.230 |
Why?
|
| Gait Ataxia | 1 | 2005 | 2 | 0.230 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 6 | 0.230 |
Why?
|
| Prefrontal Cortex | 1 | 2025 | 36 | 0.230 |
Why?
|
| Research Design | 2 | 2022 | 42 | 0.220 |
Why?
|
| RNA, Messenger | 3 | 2018 | 87 | 0.220 |
Why?
|
| Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.210 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2004 | 2 | 0.210 |
Why?
|
| Chorea | 1 | 2004 | 3 | 0.210 |
Why?
|
| Brain | 2 | 2021 | 331 | 0.210 |
Why?
|
| Alleles | 2 | 2016 | 89 | 0.210 |
Why?
|
| Consensus | 2 | 2022 | 21 | 0.200 |
Why?
|
| Retrospective Studies | 4 | 2015 | 584 | 0.200 |
Why?
|
| Age of Onset | 3 | 2016 | 27 | 0.200 |
Why?
|
| Activities of Daily Living | 2 | 2015 | 75 | 0.200 |
Why?
|
| United States | 1 | 2025 | 502 | 0.190 |
Why?
|
| Cerebral Hemorrhage | 1 | 2021 | 26 | 0.170 |
Why?
|
| Biomechanical Phenomena | 3 | 2016 | 156 | 0.170 |
Why?
|
| Brain Ischemia | 1 | 2021 | 27 | 0.160 |
Why?
|
| Neuropsychological Tests | 2 | 2020 | 309 | 0.160 |
Why?
|
| Time Factors | 2 | 2020 | 374 | 0.160 |
Why?
|
| Hearing Aids | 1 | 2020 | 1 | 0.160 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.160 |
Why?
|
| Cochlear Implantation | 1 | 2020 | 3 | 0.160 |
Why?
|
| Time and Motion Studies | 1 | 2020 | 8 | 0.160 |
Why?
|
| Speech Perception | 1 | 2020 | 8 | 0.160 |
Why?
|
| Pilot Projects | 1 | 2020 | 94 | 0.150 |
Why?
|
| Motor Activity | 1 | 2020 | 83 | 0.150 |
Why?
|
| Sample Size | 1 | 2018 | 5 | 0.140 |
Why?
|
| Research Subjects | 1 | 2018 | 5 | 0.140 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 33 | 0.140 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2018 | 22 | 0.140 |
Why?
|
| Genotype | 2 | 2016 | 114 | 0.130 |
Why?
|
| Cognition | 1 | 2020 | 337 | 0.130 |
Why?
|
| Mosaicism | 1 | 2016 | 5 | 0.130 |
Why?
|
| Gait | 2 | 2016 | 93 | 0.130 |
Why?
|
| Siblings | 1 | 2016 | 7 | 0.130 |
Why?
|
| Child | 2 | 2015 | 339 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 28 | 0.120 |
Why?
|
| Congresses as Topic | 1 | 2016 | 10 | 0.120 |
Why?
|
| Young Adult | 2 | 2015 | 421 | 0.120 |
Why?
|
| Mutation | 2 | 2007 | 101 | 0.120 |
Why?
|
| Adolescent | 2 | 2015 | 488 | 0.120 |
Why?
|
| Computers | 1 | 2015 | 6 | 0.120 |
Why?
|
| Early Diagnosis | 1 | 2015 | 13 | 0.120 |
Why?
|
| Regression Analysis | 1 | 2015 | 40 | 0.120 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 15 | 0.120 |
Why?
|
| Reaction Time | 1 | 2015 | 39 | 0.120 |
Why?
|
| Sex Factors | 3 | 2011 | 129 | 0.120 |
Why?
|
| England | 1 | 2015 | 3 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2015 | 54 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 62 | 0.110 |
Why?
|
| Incidence | 1 | 2015 | 165 | 0.110 |
Why?
|
| Hyperkinesis | 1 | 2013 | 8 | 0.100 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 8 | 0.100 |
Why?
|
| Cerebellar Diseases | 1 | 2013 | 3 | 0.100 |
Why?
|
| Animals | 1 | 2016 | 1349 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2022 | 7 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2011 | 60 | 0.080 |
Why?
|
| Neurologic Examination | 2 | 2006 | 17 | 0.070 |
Why?
|
| Family Health | 2 | 2007 | 12 | 0.070 |
Why?
|
| Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 9 | 0.070 |
Why?
|
| Guidelines as Topic | 1 | 2007 | 13 | 0.070 |
Why?
|
| Point Mutation | 1 | 2007 | 14 | 0.060 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2007 | 8 | 0.060 |
Why?
|
| Carbidopa | 1 | 2006 | 2 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2006 | 9 | 0.060 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2006 | 5 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2006 | 10 | 0.060 |
Why?
|
| Levodopa | 1 | 2006 | 6 | 0.060 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2006 | 11 | 0.060 |
Why?
|
| Anxiety Disorders | 1 | 2006 | 35 | 0.060 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2025 | 3 | 0.060 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 284 | 0.060 |
Why?
|
| Cerebellum | 1 | 2005 | 8 | 0.060 |
Why?
|
| Atrophy | 1 | 2005 | 15 | 0.060 |
Why?
|
| DNA Mutational Analysis | 1 | 2005 | 23 | 0.060 |
Why?
|
| Syndrome | 1 | 2005 | 30 | 0.060 |
Why?
|
| Health Surveys | 1 | 2005 | 16 | 0.060 |
Why?
|
| Age Factors | 1 | 2005 | 181 | 0.050 |
Why?
|
| Stroke | 1 | 2005 | 71 | 0.050 |
Why?
|
| Prodromal Symptoms | 1 | 2024 | 7 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2004 | 16 | 0.050 |
Why?
|
| DNA Repeat Expansion | 1 | 2004 | 5 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2004 | 11 | 0.050 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 52 | 0.050 |
Why?
|
| Disability Evaluation | 2 | 2016 | 60 | 0.050 |
Why?
|
| Biomarkers | 1 | 2024 | 141 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 150 | 0.050 |
Why?
|
| Task Performance and Analysis | 2 | 2013 | 18 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2021 | 27 | 0.040 |
Why?
|
| Noise | 1 | 2020 | 4 | 0.040 |
Why?
|
| Cochlear Implants | 1 | 2020 | 4 | 0.040 |
Why?
|
| Posture | 1 | 2016 | 13 | 0.030 |
Why?
|
| Video Recording | 1 | 2014 | 5 | 0.030 |
Why?
|
| Prevalence | 1 | 2014 | 72 | 0.030 |
Why?
|
| Movement | 1 | 2013 | 25 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 28 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 32 | 0.020 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 19 | 0.020 |
Why?
|
| Linear Models | 1 | 2011 | 64 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 203 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 100 | 0.020 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 4 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 11 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2007 | 207 | 0.020 |
Why?
|
| Mass Screening | 1 | 2007 | 31 | 0.020 |
Why?
|
| Disease Progression | 1 | 2007 | 157 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 333 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 13 | 0.010 |
Why?
|
| California | 1 | 2004 | 16 | 0.010 |
Why?
|